Corcept Therapeutics CDO Sells 20,000 Shares for $703,656
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 11 2026
0mins
Should l Buy CORT?
Source: NASDAQ.COM
- Executive Transaction: William Guyer, the Chief Development Officer of Corcept Therapeutics, sold 20,000 shares on Tuesday through open-market transactions totaling $703,656, indicating a strategic liquidity management by the executive.
- Options Exercise: The transaction involved exercising stock options for 250,000 shares, and while his direct holdings decreased, Guyer retains significant options, suggesting a continued positive outlook on the company's future.
- Financial Performance: Corcept reported third-quarter revenue of $207.6 million, up from $182.5 million a year earlier, driven by ongoing growth in Korlym prescriptions, enhancing the company's competitive position in the market.
- Outlook Reaffirmation: Despite facing regulatory challenges from the FDA, management reaffirmed full-year revenue guidance of $800 million to $850 million, demonstrating the company's financial flexibility and potential for sustained growth amid uncertainty.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 51.050
Low
50.00
Averages
91.00
High
121.00
Current: 51.050
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Reports Q1 2026 Earnings and Raises Revenue Guidance
- Revenue Growth: Corcept Therapeutics reported Q1 2026 revenue of $164.9 million, up from $157.2 million in the prior year, indicating sustained market demand that is expected to enhance future profitability.
- Guidance Upgrade: Management raised the 2026 revenue guidance to $950 million to $1.05 billion, primarily driven by strong performance in the endocrinology business and the new oncology drug Lifyorli, reflecting confidence in future growth.
- FDA Approval Impact: Lifyorli was included in the National Comprehensive Cancer Network (NCCN) guidelines just 15 days post-FDA approval, which is expected to accelerate market adoption and enhance the company's competitiveness in oncology.
- Long-term Growth Outlook: Management anticipates that the Cushing's Syndrome business will reach at least $2 billion in annual revenue by 2030, while Lifyorli is expected to exceed $1 billion in annual revenue in the U.S., demonstrating strong confidence in future market potential.
See More
CORCEPT THERAPEUTICS INC ANTICIPATES PROFITABILITY BY Q2 2026
Company Overview: Corcept Therapeutics is anticipating a return to profitability in the second quarter of 2026.
Financial Expectations: The company is focusing on strategies to enhance its financial performance and achieve sustainable growth.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors can join the class action without any upfront fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the confidence in FDA approval for its drug relacorilant, despite the FDA expressing concerns about the adequacy of clinical evidence, which exposed investors to potential losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved multiple large settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this field.
See More
Corcept Presents New Data on Lifyorli at ASCO 2026
- Clinical Trial Data Presentation: Corcept Therapeutics will present new data from the Phase 3 ROSELLA trial of Lifyorli™ plus nab-paclitaxel for platinum-resistant ovarian cancer at the 2026 ASCO Annual Meeting, which is expected to enhance its competitive position in the market.
- FDA Approval of New Drug: Lifyorli received FDA approval in March 2026 as the first selective glucocorticoid receptor antagonist for platinum-resistant ovarian cancer, marking a significant advancement for Corcept in oncology treatment.
- Scarcity of Treatment Options: Approximately 20,000 women in the U.S. are candidates for new therapies for platinum-resistant ovarian cancer each year, and the introduction of Lifyorli will provide new treatment options for these patients, addressing market demand and potentially boosting company performance.
- Collaborative Research Background: The ROSELLA trial was conducted in collaboration with multiple international oncology research organizations, demonstrating Corcept's influence and collaborative capabilities in global oncology research, further solidifying its industry position.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Lawsuit Timeline: Investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, should be aware of the lead plaintiff deadline on April 21, 2026, and act promptly to protect their rights.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any upfront costs through a contingency fee arrangement, which alleviates the financial burden on affected investors and encourages broader participation.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record, thus investors should carefully select experienced legal counsel.
- FDA Regulatory Risks: The lawsuit alleges that Corcept misrepresented the confidence in its relacorilant NDA, failing to disclose FDA concerns regarding clinical evidence, which resulted in investor losses when the truth was revealed.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman law firm reminds shareholders of Corcept Therapeutics that the lead plaintiff deadline for the pending securities class action is April 21, 2026, urging investors to submit their losses before this date to participate in the lawsuit and seek compensation.
- Allegations Overview: The lawsuit alleges that Corcept concealed critical communications with the FDA regarding its lead drug candidate, relacorilant, during the class period from October 31, 2024, to December 30, 2025, leading to investor misunderstandings about its approval prospects and impacting shareholder investment decisions.
- Information Discrepancy: The complaint claims that Corcept's management was internally informed of potential failure for relacorilant but externally conveyed optimistic approval expectations, indicating a severe lack of corporate governance and transparency that may have resulted in significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further underscoring the company's accountability and transparency responsibilities.
See More
Corcept Therapeutics Reports Q1 2026 Earnings and Raises Revenue Guidance
- Revenue Growth: Corcept Therapeutics reported Q1 2026 revenue of $164.9 million, up from $157.2 million in the prior year, indicating sustained market demand that is expected to enhance future profitability.
- Guidance Upgrade: Management raised the 2026 revenue guidance to $950 million to $1.05 billion, primarily driven by strong performance in the endocrinology business and the new oncology drug Lifyorli, reflecting confidence in future growth.
- FDA Approval Impact: Lifyorli was included in the National Comprehensive Cancer Network (NCCN) guidelines just 15 days post-FDA approval, which is expected to accelerate market adoption and enhance the company's competitiveness in oncology.
- Long-term Growth Outlook: Management anticipates that the Cushing's Syndrome business will reach at least $2 billion in annual revenue by 2030, while Lifyorli is expected to exceed $1 billion in annual revenue in the U.S., demonstrating strong confidence in future market potential.
See More
CORCEPT THERAPEUTICS INC ANTICIPATES PROFITABILITY BY Q2 2026
Company Overview: Corcept Therapeutics is anticipating a return to profitability in the second quarter of 2026.
Financial Expectations: The company is focusing on strategies to enhance its financial performance and achieve sustainable growth.
See More
Corcept Lawsuit Reminder for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Corcept (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, that they must apply to be lead plaintiff by April 21, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors can join the class action without any upfront fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that Corcept made false statements regarding the confidence in FDA approval for its drug relacorilant, despite the FDA expressing concerns about the adequacy of clinical evidence, which exposed investors to potential losses.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved multiple large settlements, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and successful track record in this field.
See More
Corcept Presents New Data on Lifyorli at ASCO 2026
- Clinical Trial Data Presentation: Corcept Therapeutics will present new data from the Phase 3 ROSELLA trial of Lifyorli™ plus nab-paclitaxel for platinum-resistant ovarian cancer at the 2026 ASCO Annual Meeting, which is expected to enhance its competitive position in the market.
- FDA Approval of New Drug: Lifyorli received FDA approval in March 2026 as the first selective glucocorticoid receptor antagonist for platinum-resistant ovarian cancer, marking a significant advancement for Corcept in oncology treatment.
- Scarcity of Treatment Options: Approximately 20,000 women in the U.S. are candidates for new therapies for platinum-resistant ovarian cancer each year, and the introduction of Lifyorli will provide new treatment options for these patients, addressing market demand and potentially boosting company performance.
- Collaborative Research Background: The ROSELLA trial was conducted in collaboration with multiple international oncology research organizations, demonstrating Corcept's influence and collaborative capabilities in global oncology research, further solidifying its industry position.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Lawsuit Timeline: Investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, should be aware of the lead plaintiff deadline on April 21, 2026, and act promptly to protect their rights.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any upfront costs through a contingency fee arrangement, which alleviates the financial burden on affected investors and encourages broader participation.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record, thus investors should carefully select experienced legal counsel.
- FDA Regulatory Risks: The lawsuit alleges that Corcept misrepresented the confidence in its relacorilant NDA, failing to disclose FDA concerns regarding clinical evidence, which resulted in investor losses when the truth was revealed.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman law firm reminds shareholders of Corcept Therapeutics that the lead plaintiff deadline for the pending securities class action is April 21, 2026, urging investors to submit their losses before this date to participate in the lawsuit and seek compensation.
- Allegations Overview: The lawsuit alleges that Corcept concealed critical communications with the FDA regarding its lead drug candidate, relacorilant, during the class period from October 31, 2024, to December 30, 2025, leading to investor misunderstandings about its approval prospects and impacting shareholder investment decisions.
- Information Discrepancy: The complaint claims that Corcept's management was internally informed of potential failure for relacorilant but externally conveyed optimistic approval expectations, indicating a severe lack of corporate governance and transparency that may have resulted in significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, where providing original information may yield rewards of up to 30% of any successful recovery, further underscoring the company's accountability and transparency responsibilities.
See More
